glp 1 receptor agonists and kidney protection GLP-1 next-generation metabolic hormone therapies in chronic disease Role of GLP1 RA in
Description
Earlier this year, Blue Cross Blue Shield said five GLP-1 drugs now account for nearly 20% of its pharmacy spend.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for diabetes and obesity, exhibit pleiotropic effectsincluding anti-inflammatory, ...
The most common designs are observational studies
But theres a tradeoff
Achieve Sustainable Results With Personalized Care.
Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D
